ReviewAdvances in chronic kidney disease2014
Novel biomarkers in glomerular disease.
Review in Advances in chronic kidney disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Urinary nephrin-a potential marker of early glomerular injury: a systematic review and meta-analysis.Journal of nephrology · 2024Pooled it
- Metabolome panels as potential noninvasive biomarkers for primary glomerulonephritis sub-types: meta-analysis of profiling metabolomics studies.Scientific reports · 2023Pooled it
- Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression.PloS one · 2019Trial
- MHC class II and PLA2R investigating the epitope presentation deficits driving antibody production in membranous nephropathy.International urology and nephrology · 2026Review
- A noninvasive method of diagnosing membranous nephropathy using exosomes derived from urine.Kidney research and clinical practice · 2026Article
- Development of a multiple urinary biomarker model to predict the tubulointerstitial fibrosis area in patients with primary IgA Nephropathy.BMC nephrology · 2025Article
- Keratin Expression in Podocytopathies, ANCA-Associated Vasculitis and IgA Nephropathy.International journal of molecular sciences · 2024Article
- How to take advantage of easily available biomarkers in patients with IgA nephropathy: IgA and C3 in serum and kidney biopsies.Pediatric nephrology (Berlin, Germany) · 2023Review
- COSMC expression as a predictor of remission in IgA nephropathy.International urology and nephrology · 2023Article
- Oxidative stress and macrophage infiltration in IgA nephropathy.Journal of nephrology · 2022Article
- The Role of Complement Component C3 Activation in the Clinical Presentation and Prognosis of IgA Nephropathy-A National Study in Children.Journal of clinical medicine · 2021Article
- Urinary expression of long non-coding RNA TUG1 in non-diabetic patients with glomerulonephritides.Biomedical reports · 2021Article
- The Feasibility of Targeted Magnetic Iron Oxide Nanoagent for Noninvasive IgA Nephropathy Diagnosis.Frontiers in bioengineering and biotechnology · 2021Article
- The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases.International journal of molecular sciences · 2020Review
- Does the renal expression of Toll-like receptors play a role in patients with IgA nephropathy?Journal of nephrology · 2020Article
- Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Renal Function Decline in Patients With Glomerular Diseases.Frontiers in cell and developmental biology · 2020Article
- Association of OSAHS Hypoxia Indicators with Early Renal Injury and Serum Fibroblast Growth Factor 21 in Obese Type 2 Diabetic Patients.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019Article
- Candidate Urine Peptide Biomarkers for IgA Nephropathy: Where Are We Now?Disease markers · 2018Review
- Markers for the progression of IgA nephropathy.Journal of nephrology · 2016Review
- The kidney: function, cells and biomarkers.Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Glomerular diseases are major contributors to the global burden of end-stage kidney disease. The clinical course and outcome of these disorders are extremely variable and difficult to predict. The clinical trajectories range from a benign and spontaneously remitting condition to a symptomatic and rapidly progressive disease. The diagnosis is based entirely on the evaluation of kidney biopsy, but this invasive procedure carries multiple risks and often fails to predict the clinical course or responsiveness to treatment. However, more recent advances in genetics and molecular biology have facilitated elucidation of novel pathogenic mechanisms of these disorders. These discoveries fuel the development of novel biomarkers and offer prospects of noninvasive diagnosis and improved prognostication. Our review focuses on the most promising novel biomarkers that have recently emerged for the major types of glomerular diseases, including immunoglobulin A nephropathy, membranous nephropathy, focal segmental glomerulosclerosis, and membranoproliferative glomerulonephritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.